Insider Activity and Operational Developments at Aquestive Therapeutics
Recent filings reveal a notable insider transaction involving Daniel Barber, President and CEO of Aquestive Therapeutics, Inc. (NASDAQ:AQST). On May 15, 2026, Mr. Barber sold 8,257 shares of the company's common stock. The aggregate value of these sales reached $35,413, with the executed share prices fluctuating between $4.17 and $4.64 per share.
The weighted average price for the units sold was calculated at $4.2889. Following this transaction, Mr. Barber's direct holdings of Aquestive Therapeutics common stock were adjusted to 660,574 shares. The details of this sale were formally disclosed to the Securities and Exchange Commission via a Form 4 filing on May 18, 2026.
Company Performance Context
The insider selling activity is contextualized against Aquestive Therapeutics' recent financial disclosures and strategic progress. The company reported its first-quarter 2026 financial results, which demonstrated strength by exceeding various earnings benchmarks.
Specifically, the firm achieved an earnings per share (EPS) of -$0.07 for the quarter. This figure surpassed the consensus forecast of -$0.13, representing a positive surprise margin of 46.15%. Furthermore, quarterly revenue reached $14.4 million. This amount significantly exceeded the anticipated revenue of $10.9 million and marked a robust 66% increase when compared to the corresponding period in the previous year.
In terms of strategic development, Aquestive also confirmed the timeline for its Anaphylm NDA resubmission. This crucial submission is scheduled for the third quarter of 2026, while the company maintained its financial guidance for the full fiscal year.
Analyst and Market View
Market sentiment remains generally positive, according to available analyst reports. Citizens recently reiterated a 'Market Outperform' rating on Aquestive Therapeutics, setting a price target of $10.00 for the stock.
Looking at broader performance metrics, the stock has delivered a 75% return over the past year. However, it is important to note that shares are currently down 35% when measured year-to-date. Analysts continue to maintain a bullish outlook, with price targets ranging from $6 to $11.
For deeper investment insights into Aquestive Therapeutics (AQST), resources such as InvestingPro offer access to over five additional ProTips and comprehensive Pro Research Reports that cover AQST alongside more than 1,400 other US equities.